Log in

NASDAQ:NTECIntec Pharma Stock Price, Forecast & News

-0.03 (-7.24 %)
(As of 08/14/2020 04:00 PM ET)
Today's Range
Now: $0.37
50-Day Range
MA: $0.36
52-Week Range
Now: $0.37
Volume8.02 million shs
Average Volume6.45 million shs
Market Capitalization$26.58 million
P/E RatioN/A
Dividend YieldN/A
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Read More
Intec Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NTEC



Sales & Book Value

Annual SalesN/A
Book Value$0.22 per share


Net Income$-47,600,000.00


Market Cap$26.58 million
Next Earnings Date11/10/2020 (Estimated)
-0.03 (-7.24 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

How has Intec Pharma's stock been impacted by Coronavirus (COVID-19)?

Intec Pharma's stock was trading at $0.2388 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NTEC stock has increased by 54.9% and is now trading at $0.37.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Intec Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Intec Pharma

When is Intec Pharma's next earnings date?

Intec Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Intec Pharma

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) announced its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.00.
View Intec Pharma's earnings history

What price target have analysts set for NTEC?

4 brokers have issued 1-year target prices for Intec Pharma's stock. Their forecasts range from $1.00 to $1.00. On average, they expect Intec Pharma's share price to reach $1.00 in the next year. This suggests a possible upside of 170.3% from the stock's current price.
View analysts' price targets for Intec Pharma

Has Intec Pharma been receiving favorable news coverage?

News articles about NTEC stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intec Pharma earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Intec Pharma

Are investors shorting Intec Pharma?

Intec Pharma saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 2,310,000 shares, a decline of 19.5% from the June 15th total of 2,870,000 shares. Based on an average daily volume of 7,900,000 shares, the days-to-cover ratio is presently 0.3 days.
View Intec Pharma's Short Interest

Who are some of Intec Pharma's key competitors?

What other stocks do shareholders of Intec Pharma own?

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the following people:
  • Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 53, Pay $786.9k)
  • Mr. Nir Sassi, Chief Financial Officer (Age 44, Pay $338.11k)
  • Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 51, Pay $394.94k)
  • Mr. Walt Addison Linscott, Chief Bus. Officer (Age 59, Pay $557.05k)
  • Dr. R. Michael Gendreau, Chief Medical Officer (Age 64, Pay $459.15k)

When did Intec Pharma IPO?

(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

Who are Intec Pharma's major shareholders?

Intec Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Integrated Wealth Concepts LLC (0.60%), Harel Insurance Investments & Financial Services Ltd. (0.53%) and Russell Investments Group Ltd. (0.15%). Company insiders that own Intec Pharma stock include Anthony J Maddaluna, Issac Silberman, Jeffrey A Meckler and Pharma Technologies Ltd Dexcel.
View institutional ownership trends for Intec Pharma

Which institutional investors are buying Intec Pharma stock?

NTEC stock was purchased by a variety of institutional investors in the last quarter, including Integrated Wealth Concepts LLC, Harel Insurance Investments & Financial Services Ltd., and Russell Investments Group Ltd.. Company insiders that have bought Intec Pharma stock in the last two years include Anthony J Maddaluna, and Jeffrey A Meckler.
View insider buying and selling activity for Intec Pharma

How do I buy shares of Intec Pharma?

Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intec Pharma's stock price today?

One share of NTEC stock can currently be purchased for approximately $0.37.

How big of a company is Intec Pharma?

Intec Pharma has a market capitalization of $26.58 million. The biotechnology company earns $-47,600,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Intec Pharma employs 38 workers across the globe.

What is Intec Pharma's official website?

The official website for Intec Pharma is www.intecpharma.com.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.